Head-To-Head Survey: BioStem Technologies (OTCMKTS:BSEM) versus CAMP4 Therapeutics (NASDAQ:CAMP)

CAMP4 Therapeutics (NASDAQ:CAMP) and BioStem Technologies (OTCMKTS:BSEM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Volatility and Risk

CAMP4 Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, BioStem Technologies has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.

Earnings & Valuation

This table compares CAMP4 Therapeutics and BioStem Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$4.22 million	63.26	-$80.40 million	($2.32)	-1.83
BioStem Technologies	$292.21 million	0.26	-$28.56 million	($1.60)	-2.69

BioStem Technologies has higher revenue and earnings than CAMP4 Therapeutics. BioStem Technologies is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for CAMP4 Therapeutics and BioStem Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1	1	7	0	2.67
BioStem Technologies	0	1	0	1	3.00

CAMP4 Therapeutics presently has a consensus target price of $9.56, indicating a potential upside of 125.00%. BioStem Technologies has a consensus target price of $9.00, indicating a potential upside of 108.82%. Given CAMP4 Therapeutics’ higher possible upside, equities research analysts plainly believe CAMP4 Therapeutics is more favorable than BioStem Technologies.

Profitability

This table compares CAMP4 Therapeutics and BioStem Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
BioStem Technologies	N/A	N/A	N/A

Summary

BioStem Technologies beats CAMP4 Therapeutics on 8 of the 13 factors compared between the two stocks.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.

About BioStem Technologies

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.